AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 147.76 Million USD | 14.82% |
| 2022 | 128.69 Million USD | -2.18% |
| 2021 | 131.55 Million USD | -56.46% |
| 2020 | 302.14 Million USD | -2.7% |
| 2019 | 310.53 Million USD | 189.2% |
| 2018 | 107.37 Million USD | 0.79% |
| 2017 | 106.53 Million USD | -1.33% |
| 2016 | 107.97 Million USD | 24.97% |
| 2015 | 86.4 Million USD | 234.06% |
| 2014 | 25.86 Million USD | -34.26% |
| 2013 | 39.34 Million USD | 97.4% |
| 2012 | 19.93 Million USD | 9.25% |
| 2011 | 18.24 Million USD | 7.45% |
| 2010 | 16.97 Million USD | -5.1% |
| 2009 | 17.89 Million USD | 25.56% |
| 2008 | 14.24 Million USD | 44.89% |
| 2007 | 9.83 Million USD | 16.61% |
| 2006 | 8.43 Million USD | 23.0% |
| 2005 | 6.85 Million USD | -82.88% |
| 2004 | 40.06 Million USD | 18.89% |
| 2003 | 33.69 Million USD | 5853.36% |
| 2002 | 566 Thousand USD | 76.88% |
| 2001 | 320 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 135.18 Million USD | -0.09% |
| 2024 Q1 | 135.31 Million USD | -8.42% |
| 2024 Q3 | 150.04 Million USD | 10.99% |
| 2023 Q3 | 137.43 Million USD | 4.32% |
| 2023 Q4 | 147.76 Million USD | 7.51% |
| 2023 FY | 147.76 Million USD | 14.82% |
| 2023 Q1 | 128.25 Million USD | -0.34% |
| 2023 Q2 | 131.74 Million USD | 2.72% |
| 2022 Q4 | 128.69 Million USD | -2.21% |
| 2022 Q1 | 122.15 Million USD | -7.14% |
| 2022 Q3 | 131.6 Million USD | 0.71% |
| 2022 FY | 128.69 Million USD | -2.18% |
| 2022 Q2 | 130.67 Million USD | 6.98% |
| 2021 FY | 131.55 Million USD | -56.46% |
| 2021 Q1 | 308.65 Million USD | 2.16% |
| 2021 Q2 | 315.99 Million USD | 2.38% |
| 2021 Q3 | 124.5 Million USD | -60.6% |
| 2021 Q4 | 131.55 Million USD | 5.67% |
| 2020 Q2 | 287.37 Million USD | -4.33% |
| 2020 FY | 302.14 Million USD | -2.7% |
| 2020 Q1 | 300.36 Million USD | -3.27% |
| 2020 Q4 | 302.14 Million USD | 4.09% |
| 2020 Q3 | 290.26 Million USD | 1.01% |
| 2019 Q2 | 101.57 Million USD | 2.53% |
| 2019 FY | 310.53 Million USD | 189.2% |
| 2019 Q1 | 99.06 Million USD | -7.74% |
| 2019 Q4 | 310.53 Million USD | 2.64% |
| 2019 Q3 | 302.53 Million USD | 197.85% |
| 2018 Q3 | 108.19 Million USD | -2.67% |
| 2018 FY | 107.37 Million USD | 0.79% |
| 2018 Q4 | 107.37 Million USD | -0.75% |
| 2018 Q2 | 111.16 Million USD | -4.65% |
| 2018 Q1 | 116.57 Million USD | 9.42% |
| 2017 Q3 | 109.53 Million USD | 2.36% |
| 2017 Q4 | 106.53 Million USD | -2.73% |
| 2017 Q1 | 105.56 Million USD | -2.24% |
| 2017 FY | 106.53 Million USD | -1.33% |
| 2017 Q2 | 107 Million USD | 1.37% |
| 2016 Q4 | 107.97 Million USD | 1.98% |
| 2016 Q3 | 105.88 Million USD | 1.31% |
| 2016 Q2 | 104.51 Million USD | 29.54% |
| 2016 Q1 | 80.68 Million USD | -6.62% |
| 2016 FY | 107.97 Million USD | 24.97% |
| 2015 Q4 | 86.4 Million USD | 115.17% |
| 2015 Q1 | 24.84 Million USD | -3.94% |
| 2015 Q2 | 30.61 Million USD | 23.23% |
| 2015 Q3 | 40.15 Million USD | 31.16% |
| 2015 FY | 86.4 Million USD | 234.06% |
| 2014 Q3 | 22.1 Million USD | 1.81% |
| 2014 Q1 | 24.29 Million USD | -38.26% |
| 2014 FY | 25.86 Million USD | -34.26% |
| 2014 Q2 | 21.71 Million USD | -10.61% |
| 2014 Q4 | 25.86 Million USD | 17.01% |
| 2013 Q2 | 19.34 Million USD | -0.95% |
| 2013 Q4 | 39.34 Million USD | 83.91% |
| 2013 FY | 39.34 Million USD | 97.4% |
| 2013 Q1 | 19.52 Million USD | -2.03% |
| 2013 Q3 | 21.39 Million USD | 10.6% |
| 2012 Q4 | 19.93 Million USD | -1.25% |
| 2012 Q2 | 21.08 Million USD | -3.87% |
| 2012 Q1 | 21.93 Million USD | 20.24% |
| 2012 FY | 19.93 Million USD | 9.25% |
| 2012 Q3 | 20.18 Million USD | -4.29% |
| 2011 FY | 18.24 Million USD | 7.45% |
| 2011 Q4 | 18.24 Million USD | 1.2% |
| 2011 Q3 | 18.02 Million USD | -6.18% |
| 2011 Q2 | 19.21 Million USD | -7.15% |
| 2011 Q1 | 20.69 Million USD | 21.88% |
| 2010 Q1 | 17.16 Million USD | -4.07% |
| 2010 FY | 16.97 Million USD | -5.1% |
| 2010 Q4 | 16.97 Million USD | -14.93% |
| 2010 Q3 | 19.96 Million USD | 4.98% |
| 2010 Q2 | 19.01 Million USD | 10.77% |
| 2009 Q3 | 17.78 Million USD | 40.32% |
| 2009 FY | 17.89 Million USD | 25.56% |
| 2009 Q1 | 5.79 Million USD | -59.34% |
| 2009 Q2 | 12.67 Million USD | 118.74% |
| 2009 Q4 | 17.89 Million USD | 0.62% |
| 2008 Q2 | 8.14 Million USD | -20.33% |
| 2008 FY | 14.24 Million USD | 44.89% |
| 2008 Q4 | 14.24 Million USD | -1.33% |
| 2008 Q3 | 14.44 Million USD | 77.34% |
| 2008 Q1 | 10.22 Million USD | 3.93% |
| 2007 Q4 | 9.83 Million USD | 19.67% |
| 2007 Q2 | 10.03 Million USD | 10.0% |
| 2007 Q1 | 9.12 Million USD | 8.18% |
| 2007 FY | 9.83 Million USD | 16.61% |
| 2007 Q3 | 8.21 Million USD | -18.11% |
| 2006 FY | 8.43 Million USD | 23.0% |
| 2006 Q1 | 6.7 Million USD | -2.19% |
| 2006 Q3 | 7.04 Million USD | 3.6% |
| 2006 Q2 | 6.8 Million USD | 1.45% |
| 2006 Q4 | 8.43 Million USD | 19.65% |
| 2005 Q2 | 43.99 Million USD | 5.44% |
| 2005 Q4 | 6.85 Million USD | -6.26% |
| 2005 Q1 | 41.72 Million USD | 4.15% |
| 2005 Q3 | 7.31 Million USD | -83.37% |
| 2005 FY | 6.85 Million USD | -82.88% |
| 2004 FY | 40.06 Million USD | 18.89% |
| 2004 Q4 | 40.06 Million USD | 0.0% |
| 2003 FY | 33.69 Million USD | 5853.36% |
| 2002 FY | 566 Thousand USD | 76.88% |
| 2001 FY | 320 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | -16.718% |
| AngioDynamics, Inc. | 112.08 Million USD | -31.832% |
| Avinger, Inc. | 19.97 Million USD | -639.856% |
| Azenta, Inc. | 351.22 Million USD | 57.928% |
| BioLife Solutions, Inc. | 75.05 Million USD | -96.885% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 96.403% |
| Daxor Corporation | 858.75 Thousand USD | -17106.71% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -805.861% |
| Femasys Inc. | 9.4 Million USD | -1471.416% |
| GlucoTrack, Inc. | 1.7 Million USD | -8551.288% |
| Harvard Bioscience, Inc. | 64.29 Million USD | -129.833% |
| Hologic, Inc. | 4.02 Billion USD | 96.33% |
| ICU Medical, Inc. | 2.25 Billion USD | 93.447% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 92.772% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -1722.627% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | -202.312% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -22290.656% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -22290.656% |
| Masimo Corporation | 1.67 Billion USD | 91.187% |
| Microbot Medical Inc. | 3.82 Million USD | -3762.101% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -489.231% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 86.845% |
| Nephros, Inc. | 3.5 Million USD | -4118.213% |
| NovoCure Limited | 783.63 Million USD | 81.144% |
| NEXGEL, Inc. | 4.78 Million USD | -2985.488% |
| NEXGEL, Inc. | 4.78 Million USD | -2985.488% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | -70.902% |
| OraSure Technologies, Inc. | 52.17 Million USD | -183.214% |
| Pro-Dex, Inc. | 23.34 Million USD | -533.012% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -798.589% |
| Predictive Oncology Inc. | 6.14 Million USD | -2304.438% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -2058.782% |
| QuidelOrtho Corporation | 3.55 Billion USD | 95.846% |
| Repligen Corporation | 853.2 Million USD | 82.681% |
| Sanara MedTech Inc. | 29.28 Million USD | -404.604% |
| STAAR Surgical Company | 102.73 Million USD | -43.826% |
| Sharps Technology, Inc. | 3.85 Million USD | -3733.066% |
| Utah Medical Products, Inc. | 7.14 Million USD | -1968.076% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 96.375% |
| Jin Medical International Ltd. | 8.92 Million USD | -1555.741% |